DrugPatentWatch Database Preview
Triamcinolone acetonide - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for triamcinolone acetonide and what is the scope of patent protection?
Triamcinolone acetonide
is the generic ingredient in twenty-six branded drugs marketed by Abbvie, Sanofi Aventis Us, Astellas, Ivax Pharms, Delcor Asset Corp, Teva, Solvay, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Cosette, Fougera Pharms, Glenmark Pharms Ltd, Lupin Atlantis, Macleods Pharms Ltd, MLV, Morton Grove, Mylan, Perrigo New York, Pharmaderm, Pharmafair, Strides Pharma, Taro, Taro Pharm Inds Ltd, Teligent Pharma Inc, Topiderm, Crown Labs, Savage Labs, Flexion Theraps Inc, Apothecon, Amneal, Parnell, Sandoz Inc, Teva Pharms Usa, Watson Labs, Allergan, Novartis, Akorn, Quagen, Saptalis Pharms, Wockhardt Bio Ag, Encube, Glenmark Pharms, Novel Labs Inc, Cmp Pharma Inc, Lyne, Perrigo Israel, Sun Pharm Inds Inc, Perrigo Uk Finco, and Rising, and is included in one hundred and twenty-nine NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Triamcinolone acetonide has seventy-three patent family members in twenty-five countries.
There are fifty-one drug master file entries for triamcinolone acetonide. Seventy suppliers are listed for this compound.
Summary for triamcinolone acetonide
| International Patents: | 73 |
| US Patents: | 5 |
| Tradenames: | 26 |
| Applicants: | 51 |
| NDAs: | 129 |
| Drug Master File Entries: | 51 |
| Suppliers / Packagers: | 70 |
| Bulk Api Vendors: | 66 |
| Clinical Trials: | 170 |
| Patent Applications: | 4,583 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for triamcinolone acetonide |
| Drug Sales Revenues: | Drug sales revenues for triamcinolone acetonide |
| DailyMed Link: | triamcinolone acetonide at DailyMed |
Recent Clinical Trials for triamcinolone acetonide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of South Florida | Phase 3 |
| ghada fouad | Phase 2/Phase 3 |
| Memorial Sloan Kettering Cancer Center | Phase 2 |
Pharmacology for triamcinolone acetonide
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for triamcinolone acetonide
US Patents and Regulatory Information for triamcinolone acetonide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delcor Asset Corp | KENALOG | triamcinolone acetonide | LOTION;TOPICAL | 011602-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Taro | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 086277-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Pharmafair | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 087922-001 | Aug 10, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Cosette | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | LOTION;TOPICAL | 089129-001 | Aug 14, 1986 | AT | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Teva Pharms Usa | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | INJECTABLE;INJECTION | 209852-001 | Oct 5, 2018 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Astellas | ARISTOCORT A | triamcinolone acetonide | CREAM;TOPICAL | 083016-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for triamcinolone acetonide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | AZMACORT | triamcinolone acetonide | AEROSOL, METERED;INHALATION | 018117-001 | Apr 23, 1982 | Start Trial | Start Trial |
| Sanofi Aventis Us | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | Start Trial | Start Trial |
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | Start Trial | Start Trial |
| Sanofi Aventis Us | NASACORT ALLERGY 24 HOUR | triamcinolone acetonide | SPRAY, METERED;NASAL | 020468-002 | Oct 11, 2013 | Start Trial | Start Trial |
| Sanofi Aventis Us | NASACORT | triamcinolone acetonide | AEROSOL, METERED;NASAL | 019798-001 | Jul 11, 1991 | Start Trial | Start Trial |
| Abbvie | AZMACORT | triamcinolone acetonide | AEROSOL, METERED;INHALATION | 018117-001 | Apr 23, 1982 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for triamcinolone acetonide
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101927551 | Start Trial |
| New Zealand | 607797 | Start Trial |
| European Patent Office | 3281631 | Start Trial |
| Chile | 2009000573 | Start Trial |
| Japan | 2013535489 | Start Trial |
| South Korea | 20100127267 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
